High-Sensitivity Cardiac Troponins (hs-cTnI and hs-cTnT)

Cardiac troponins — specifically cardiac troponin I (cTnI) and cardiac troponin T (cTnT) — are the globally recognized gold-standard circulating biomarkers for the detection of myocardial cell necrosis. They form the biological backbone of the Fourth Universal Definition of Myocardial Infarction.

The contractile apparatus of striated cardiac muscle consists of interdigitating actin thin filaments and myosin thick filaments. Troponin is a heterotrimeric protein complex anchored along the actin filament:

1. Troponin C (TnC, 18 kDa): Binds calcium ions to trigger cross-bridge cycling. It is identical in cardiac and slow-twitch skeletal muscle, and is therefore not used clinically as a cardiospecific biomarker.
2. Troponin I (cTnI, 24 kDa): The inhibitory subunit that prevents actomyosin ATPase activity in the relaxed, low-calcium state. The cardiac isoform has an unique 32-amino-acid N-terminal peptide extension absent in skeletal muscle isoforms, making cTnI 100% cardiospecific.
3. Troponin T (cTnT, 37 kDa): The tropomyosin-binding subunit that anchors the troponin complex to the actin-tropomyosin thin filament. A small amount of embryonic cTnT can be re-expressed in regenerating diseased skeletal muscle (e.g. polymyositis), giving cTnI a marginal cardiospecificity advantage over cTnT in severe myopathies.

Approximately 92% to 95% of intracellular cardiac troponin is tightly bound within structural sarcomeric myofibrils, while a cytosolic soluble pool comprises 3% to 8% (cTnI) and 6% to 8% (cTnT).

• When myocardial ischemia compromises cell membrane integrity, cytosolic troponin leaks rapidly into the interstitium and coronary microvasculature within 1 to 3 hours of injury.
• Subsequent slow, continuous degradation of the structural sarcomeric pool releases troponin complexes over 7 to 14 days, providing an extended diagnostic window.
• High-Sensitivity Assays (hs-cTn): Modern high-sensitivity assays quantify circulating troponin concentrations 10 to 100 times lower than older conventional generation assays, measuring concentrations down to single-digit nanograms per liter (ng/L or pg/mL) with a coefficient of variation (CV) ≤ 10% at the 99th percentile upper reference limit (URL).

• Specimen Type: Serum (gold-top SST) or lithium heparin plasma (green top). Plasma yields slightly lower values (~10%) than serum due to fibrinogen trapping; serial tests in the same patient must consistently use the same tube type.
• Hemolysis Interference: Severe hemolysis falsely depresses hs-cTnT measurements on certain Roche Elecsys platforms and causes variable interference with hs-cTnI.
• Biotin (Vitamin B7) Interference: High-dose biotin (frequently present in over-the-counter hair, skin, and nail supplements at doses > 5–10 mg/day) binds to streptavidin-coated magnetic beads used in many high-sensitivity troponin immunoassay platforms. This causes catastrophic false-negative troponin results in patients experiencing acute myocardial infarction! Always ask patients about biotin intake.
• Serial Timing Protocol: Rapid 0/1-hour and 0/2-hour protocols require rigorous adherence to exact sampling times (± 10 minutes) to ensure mathematical delta criteria remain clinically valid.

1. Suspected Acute Coronary Syndrome (ACS): Acute retrosternal chest discomfort, radiating left arm/jaw pain, diaphoresis, dyspnea, or unexplained syncope.
2. Atypical Ischemic Equivalents: Acute dyspnea, fatigue, epigastric pain, or nausea in diabetic, elderly, or female patients.
3. Risk Stratification in Acute Pulmonary Embolism: Demonstrating right ventricular strain and myocardial necrosis in submassive/massive PE to guide intensive monitoring or systemic thrombolysis.
4. Evaluation of Acute Myocarditis & Pericarditis: Young patients with chest pain, viral prodrome, ST-elevations, and elevated troponin in the absence of obstructive coronary disease.
5. Monitoring Cardiotoxic Oncology Chemotherapy: Surveillance in patients receiving anthracyclines, immune checkpoint inhibitors (myocarditis), or HER2-targeted agents (trastuzumab).

┌─────────────────────────────────────────────────────────────┐
│          ESC 0/1-HOUR HIGH-SENSITIVITY PROTOCOL             │
├─────────────────────────────────────────────────────────────┤
│ Step 1: Draw Baseline (0h) hs-cTn Immediately on Arrival   │
│         ├─ If 0h hs-cTn < 4 - 5 ng/L AND chest pain > 3h:   │
│         │  → RULE-OUT ACS immediately (NPV > 99.5%)         │
│         ├─ If 0h hs-cTn >= 52 ng/L (marked elevation):      │
│         │  → Direct RULE-IN for Acute Myocardial Necrosis   │
│         └─ If intermediate: Proceed to 1-Hour Protocol      │
├─────────────────────────────────────────────────────────────┤
│ Step 2: Draw 1-Hour Repeat hs-cTn (Exact Timing)            │
│         Calculate Absolute 1h Delta: |1h hs-cTn - 0h hs-cTn|│
│         ├─ 1h Delta < 2 - 3 ng/L AND 0h < 12 ng/L:          │
│         │  → RULE-OUT (Safe for discharge / early stress)   │
│         ├─ 1h Delta >= 5 ng/L (hs-cTnI) or >= 5 ng/L (cTnT):│
│         │  → RULE-IN Acute NSTEMI (PPV > 75 - 85%)          │
│         └─ Intermediate (Delta 3 - 5 ng/L):                 │
│            → Observe; draw 3h troponin and perform echo     │
├─────────────────────────────────────────────────────────────┤
│ Step 3: Differentiate Type 1 MI vs Type 2 MI vs Injury      │
│         ├─ Type 1 MI: Plaque rupture, acute thrombus        │
│         │  (Requires DAPT, anticoagulation, invasive cath)  │
│         ├─ Type 2 MI: Supply/demand mismatch (tachycardia,  │
│         │  sepsis, severe anemia, hypoxemia)                │
│         │  (Treat underlying etiology; restore perfusion)   │
│         └─ Non-Ischemic Injury: Stable elevation (CKD, heart│
│            failure, myocarditis) with delta < 20%           │
└─────────────────────────────────────────────────────────────┘

• Macrotroponin: Formed when cardiac troponin forms circulating immune complexes with endogenous autoantibodies (IgG). Macrotroponin has an abnormally prolonged half-life, producing persistent, chronic, non-dynamic false elevations of troponin (> 50–200 ng/L) in completely healthy individuals. Differentiated via polyethylene glycol (PEG) precipitation.
• Heterophile Antibodies / Human Anti-Mouse Antibodies (HAMA): Non-specific antibodies that bridge the capture and detection antibodies in animal-derived immunoassays, causing artifactual false-positive troponin elevations.
• Biotin Megadoses: Directly neutralizes streptavidin reagents, yielding falsely suppressed (undetectable) troponin during active massive myocardial infarction.

1. The "Troponin = Myocardial Infarction" Reflex: Troponin is an organ-specific marker of cardiomyocyte necrosis, NOT a disease-specific marker of coronary artery thrombosis. Failing to distinguish acute Type 1 MI from Type 2 supply-demand mismatch in a septic patient leads to inappropriate therapeutic anticoagulation and bleeding.
2. Ignoring the Delta in Chronic Kidney Disease: Over 70% of asymptomatic patients on chronic hemodialysis have baseline hs-cTnT above the 99th percentile URL due to uremic cardiomyopathy. An isolated elevated troponin in a dialysis patient does NOT diagnose NSTEMI; an acute dynamic change (relative delta $> 20\%$ or absolute delta meeting assay criteria) is required.
3. The "Too Early" Rule-Out Fallacy: In patients presenting within 1 hour of chest pain onset, initial troponin may be undetectable. High-sensitivity protocols require at least 3 hours of symptom duration before applying the immediate single-sample rule-out threshold.

• The "Rule of 99th Percentile": Under the Universal Definition, an MI diagnosis strictly requires at least ONE troponin value above the 99th percentile URL. If all serial troponins are below the 99th percentile, an acute MI cannot be diagnosed (it is classified as Unstable Angina if ischemic pain is present).
• cTnI vs cTnT Cardiospecificity: cTnI is purely cardiac (encoded by the TNNI3 gene) and NEVER expressed in skeletal muscle under any circumstances. cTnT is encoded by TNNT2, and tiny amounts can be expressed in regenerating diseased skeletal muscle (e.g. in Duchenne muscular dystrophy or polymyositis).
• Troponin vs CK-MB for Re-infarction: Because troponin remains elevated in blood for up to 10 to 14 days post-MI, detecting early re-infarction occurring within 3 to 7 days is difficult. CK-MB normalizes within 48 to 72 hours; a secondary rise in CK-MB is the classic board answer for diagnosing early re-infarction (though serial troponin acute delta > 20% is now accepted).

• Complete Blood Count (CBC): Evaluates severe anemia precipitating Type 2 supply-demand myocardial infarction (Complete Blood Count).
• Renal Function Tests: Evaluates baseline creatinine clearance and uremic cardiomyopathy (Renal Function Tests).
• Inflammatory Markers (CRP, ESR): Assesses acute systemic inflammation in pericarditis or myocarditis (Inflammatory Markers).
• 12-Lead Electrocardiogram (ECG): Mandatory concurrent investigation performed and interpreted within 10 minutes of patient arrival.
• Transthoracic Echocardiography (TTE): Evaluates regional wall motion abnormalities (RWMA), left ventricular ejection fraction, and pericardial effusion.